{
    "hands_on_practices": [
        {
            "introduction": "The journey of creating a gene therapy begins with fundamental design constraints. Among the most critical for Adeno-Associated Virus (AAV) vectors is the strict packaging limit of the viral capsid, which dictates the maximum size of the therapeutic genetic payload. This exercise  provides hands-on practice in calculating the available space for a transgene's open reading frame (ORF) after accounting for all essential non-coding elements, such as the inverted terminal repeats (ITRs) and various regulatory sequences. Mastering this calculation is the first step in determining the feasibility of using an AAV vector for a given gene of interest.",
            "id": "5016982",
            "problem": "A translational medicine team is designing a single-stranded Adeno-Associated Virus (AAV) gene therapy vector for clinical use. The capsid imposes an upper bound on the length of the packaged genome. In AAV, the genome that is packaged includes both essential Inverted Terminal Repeats (ITRs), and the remaining portion available for the expression cassette must accommodate all regulatory elements needed for transcription, RNA processing, and post-transcriptional enhancement.\n\nAssume the following scenario:\n- The total AAV packaging limit (including both ITRs) is $4.7$ kilobases (kb), and use $1 \\text{ kb} = 1000 \\text{ base pairs (bp)}$.\n- Each ITR is $145$ bp.\n- The expression cassette will include the following regulatory elements, each considered necessary for robust expression in human somatic cells:\n  - A cytomegalovirus promoter (CMV promoter) of $600$ bp.\n  - A generic enhancer module of $300$ bp.\n  - A synthetic intron (to enhance transcriptional output and mRNA maturation) of $500$ bp.\n  - A woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) of $600$ bp.\n  - A polyadenylation (polyA) signal of $250$ bp.\n\nStarting from foundational definitions about vector genome composition and packaging constraints, derive an expression for the maximum open reading frame (ORF) length $L_{\\mathrm{ORF}}$ available for the coding sequence as a function of the total packaging limit, the ITR lengths, and the regulatory element lengths. Then, compute $L_{\\mathrm{ORF}}$ for the values specified above. Round your final numerical result to four significant figures and express it in base pairs (bp).",
            "solution": "The problem statement has been validated and is deemed valid. It is scientifically grounded in the principles of molecular biology and gene therapy vector design, is well-posed with sufficient and consistent data, and is expressed in objective language. There are no identifiable flaws.\n\nThe problem requires the derivation of an expression for the maximum length of an open reading frame (ORF), denoted as $L_{\\mathrm{ORF}}$, that can be packaged into an Adeno-Associated Virus (AAV) vector, and then to compute this length using the provided values.\n\nThe fundamental principle governing AAV vector design is that the total length of the single-stranded DNA genome to be packaged must not exceed the capsid's packaging capacity. We are given this total packaging limit, $L_{\\mathrm{total}}$. To maximize the length of the variable component, $L_{\\mathrm{ORF}}$, we must assume that the total length of the constructed genome is exactly equal to this limit.\n$$L_{\\mathrm{genome}} = L_{\\mathrm{total}}$$\nThe genome to be packaged, $L_{\\mathrm{genome}}$, is composed of several functional parts ligated together in a specific order. These parts are the two Inverted Terminal Repeats (ITRs) that flank the expression cassette. The expression cassette itself contains the necessary regulatory elements and the therapeutic ORF.\n\nThe total length of the genome is the sum of the lengths of its components:\n$$L_{\\mathrm{genome}} = (\\text{length of two ITRs}) + (\\text{length of the expression cassette})$$\nThe AAV genome is flanked by two ITRs, each of length $L_{\\mathrm{ITR}}$. Therefore, the total length contributed by the ITRs is $2 \\cdot L_{\\mathrm{ITR}}$.\n\nThe expression cassette contains all other elements. The total length of the regulatory elements can be defined as $L_{\\mathrm{reg}}$, which is the sum of the lengths of the promoter ($L_{\\mathrm{promoter}}$), enhancer ($L_{\\mathrm{enhancer}}$), intron ($L_{\\mathrm{intron}}$), WPRE ($L_{\\mathrm{WPRE}}$), and polyadenylation signal ($L_{\\mathrm{polyA}}$).\n$$L_{\\mathrm{reg}} = L_{\\mathrm{promoter}} + L_{\\mathrm{enhancer}} + L_{\\mathrm{intron}} + L_{\\mathrm{WPRE}} + L_{\\mathrm{polyA}}$$\nThe expression cassette's total length is the sum of the regulatory elements' length and the ORF's length:\n$$L_{\\mathrm{cassette}} = L_{\\mathrm{reg}} + L_{\\mathrm{ORF}}$$\nCombining these components, the total genome length can be expressed as:\n$$L_{\\mathrm{total}} = 2 \\cdot L_{\\mathrm{ITR}} + L_{\\mathrm{reg}} + L_{\\mathrm{ORF}}$$\nSubstituting the expanded form of $L_{\\mathrm{reg}}$ yields the full relationship:\n$$L_{\\mathrm{total}} = 2 \\cdot L_{\\mathrm{ITR}} + L_{\\mathrm{promoter}} + L_{\\mathrm{enhancer}} + L_{\\mathrm{intron}} + L_{\\mathrm{WPRE}} + L_{\\mathrm{polyA}} + L_{\\mathrm{ORF}}$$\nTo find the maximum available length for the ORF, we rearrange this equation to solve for $L_{\\mathrm{ORF}}$:\n$$L_{\\mathrm{ORF}} = L_{\\mathrm{total}} - 2 \\cdot L_{\\mathrm{ITR}} - (L_{\\mathrm{promoter}} + L_{\\mathrm{enhancer}} + L_{\\mathrm{intron}} + L_{\\mathrm{WPRE}} + L_{\\mathrm{polyA}})$$\nThis is the general expression for the maximum ORF length.\n\nNow, we will compute the numerical value for $L_{\\mathrm{ORF}}$ using the given data. First, all lengths must be in the same unit, which will be base pairs (bp).\nThe total packaging limit is given as $L_{\\mathrm{total}} = 4.7$ kb. Using the conversion $1 \\text{ kb} = 1000 \\text{ bp}$:\n$$L_{\\mathrm{total}} = 4.7 \\text{ kb} \\times \\frac{1000 \\text{ bp}}{1 \\text{ kb}} = 4700 \\text{ bp}$$\nThe lengths of the other components are given in bp:\n- Length of one ITR: $L_{\\mathrm{ITR}} = 145$ bp.\n- Promoter length: $L_{\\mathrm{promoter}} = 600$ bp.\n- Enhancer length: $L_{\\mathrm{enhancer}} = 300$ bp.\n- Intron length: $L_{\\mathrm{intron}} = 500$ bp.\n- WPRE length: $L_{\\mathrm{WPRE}} = 600$ bp.\n- PolyA signal length: $L_{\\mathrm{polyA}} = 250$ bp.\n\nFirst, calculate the total length of the two ITRs:\n$$2 \\cdot L_{\\mathrm{ITR}} = 2 \\cdot 145 \\text{ bp} = 290 \\text{ bp}$$\nNext, calculate the sum of the lengths of all regulatory elements, $L_{\\mathrm{reg}}$:\n$$L_{\\mathrm{reg}} = 600 \\text{ bp} + 300 \\text{ bp} + 500 \\text{ bp} + 600 \\text{ bp} + 250 \\text{ bp} = 2250 \\text{ bp}$$\nNow, substitute these values into the expression for $L_{\\mathrm{ORF}}$:\n$$L_{\\mathrm{ORF}} = L_{\\mathrm{total}} - 2 \\cdot L_{\\mathrm{ITR}} - L_{\\mathrm{reg}}$$\n$$L_{\\mathrm{ORF}} = 4700 \\text{ bp} - 290 \\text{ bp} - 2250 \\text{ bp}$$\n$$L_{\\mathrm{ORF}} = 4700 \\text{ bp} - 2540 \\text{ bp}$$\n$$L_{\\mathrm{ORF}} = 2160 \\text{ bp}$$\nThe calculated value is $2160$ bp. The problem requires the result to be rounded to four significant figures. The number $2160$ is an exact integer. To express it with four significant figures unambiguously, it is best written in scientific notation as $2.160 \\times 10^3$.",
            "answer": "$$\\boxed{2.160 \\times 10^3}$$"
        },
        {
            "introduction": "Once a vector is designed, its ability to successfully transduce target cells must be quantified. This process is not a simple one-to-one event; it involves a cascade of probabilistic steps, from receptor binding to nuclear entry. This practice problem  guides you through modeling this complex process by calculating an effective multiplicity of infection (MOI) and using the Poisson distribution—a cornerstone of quantitative virology—to predict the fraction of cells that will be successfully transduced. This skill is essential for designing experiments and interpreting results, connecting the physical dose of a vector to its biological activity.",
            "id": "5017047",
            "problem": "A translational medicine team is optimizing an in vitro dosing strategy for Adeno-Associated Virus (AAV) gene delivery to primary human hepatocytes. The vector preparation has a measured physical titer of $4.0 \\times 10^{11}$ vector genomes per milliliter (vg/mL). A single dose consisting of $50\\,\\mu\\text{L}$ of this preparation is added to a culture containing $3.0 \\times 10^{7}$ hepatocytes. Based on independent and well-characterized steps in the AAV life cycle, the following efficiencies apply uniformly to all particles in this exposure: receptor-binding efficiency $0.05$, internalization efficiency $0.40$, endosomal escape efficiency $0.25$, nuclear entry and second-strand synthesis success probability $0.30$, fraction of full capsids (i.e., capsids containing complete vector genomes) $0.60$, and survival fraction in the presence of neutralizing antibodies $0.60$. Assume the following foundational principles:\n- The multiplicity of infection (MOI) is defined as the average number of productive genome delivery events per cell.\n- Independent Bernoulli filtering steps multiplicatively reduce the expected number of productive delivery events.\n- If productive genome delivery events to each cell are independent and rare, the number of such events per cell is well modeled by a Poisson distribution.\n\nUsing these bases, derive the mean number of productive genome delivery events per cell and from it compute the predicted fraction of transduced cells after this single exposure, defined as the fraction of cells that receive at least one productive genome delivery event. Express your final result as a dimensionless decimal and round your answer to four significant figures.",
            "solution": "The problem statement must first be validated for scientific soundness, completeness, and objectivity.\n\n### Step 1: Extract Givens\nThe following data and principles are explicitly provided in the problem statement:\n-   Vector preparation physical titer, $T_{phys}$: $4.0 \\times 10^{11}$ vector genomes per milliliter (vg/mL).\n-   Dose volume, $V_{dose}$: $50\\,\\mu\\text{L}$.\n-   Number of hepatocytes, $N_{cell}$: $3.0 \\times 10^{7}$.\n-   Receptor-binding efficiency, $\\eta_{bind}$: $0.05$.\n-   Internalization efficiency, $\\eta_{int}$: $0.40$.\n-   Endosomal escape efficiency, $\\eta_{esc}$: $0.25$.\n-   Nuclear entry and second-strand synthesis success probability, $\\eta_{nuc}$: $0.30$.\n-   Fraction of full capsids, $\\eta_{full}$: $0.60$.\n-   Survival fraction in the presence of neutralizing antibodies, $\\eta_{surv}$: $0.60$.\n-   Definition: Multiplicity of infection (MOI) is the average number of productive genome delivery events per cell.\n-   Principle 1: Independent Bernoulli filtering steps multiplicatively reduce the expected number of productive delivery events.\n-   Principle 2: The number of productive genome delivery events per cell is well modeled by a Poisson distribution.\n-   Objective: Derive the mean number of productive genome delivery events per cell and compute the predicted fraction of transduced cells, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the required criteria.\n-   **Scientifically Grounded**: The problem is grounded in the established principles of virology and gene therapy, specifically concerning the delivery of AAV vectors. The concept of a physical titer (total particles) versus a functional or infectious titer is fundamental. The sequence of cellular events—binding, internalization, endosomal escape, and nuclear entry—is a standard and well-characterized pathway. The use of a Poisson distribution to model the number of independent, rare events (like successful viral transduction) per entity (a cell) is a standard and appropriate statistical method in biology. All efficiency values, while specific to this hypothetical scenario, are within a plausible range for *in vitro* experiments.\n-   **Well-Posed**: The problem provides all necessary quantitative data (titer, volume, cell count, efficiencies) and a clear statistical framework (Poisson distribution) to arrive at a unique numerical solution. The objective is clearly stated.\n-   **Objective**: The language is technical, precise, and devoid of subjective or ambiguous terminology.\n\n### Step 3: Verdict and Action\nThe problem is scientifically sound, self-contained, and well-posed. No flaws are identified. Therefore, the problem is deemed **valid**, and a full solution can be derived.\n\n### Solution Derivation\nThe solution proceeds by first calculating the total number of vector genomes applied to the cell culture. Then, the overall probability of a single vector genome resulting in a productive delivery event is determined by multiplying the efficiencies of all intermediate steps. This allows for the calculation of the mean number of productive events per cell, $\\lambda$, which corresponds to the problem's definition of MOI. Finally, the Poisson distribution model is used to compute the fraction of cells that receive at least one productive event.\n\nFirst, we calculate the total number of vector genomes (vg) added to the culture. The dose volume must be converted from microliters ($\\mu\\text{L}$) to milliliters (mL) to match the units of the titer.\n$$V_{dose} = 50\\,\\mu\\text{L} = 50 \\times 10^{-3}\\,\\text{mL} = 5.0 \\times 10^{-2}\\,\\text{mL}$$\nThe total number of vector genomes, $N_{vg}$, is the product of the physical titer, $T_{phys}$, and the dose volume, $V_{dose}$.\n$$N_{vg} = T_{phys} \\times V_{dose} = (4.0 \\times 10^{11}\\,\\text{vg/mL}) \\times (5.0 \\times 10^{-2}\\,\\text{mL}) = 20 \\times 10^{9}\\,\\text{vg} = 2.0 \\times 10^{10}\\,\\text{vg}$$\n\nNext, we calculate the overall efficiency, $\\eta_{total}$, which is the probability that a randomly selected particle from the preparation will result in a productive genome delivery event. According to the problem's principles, this is the product of all individual efficiency factors.\n$$\\eta_{total} = \\eta_{full} \\times \\eta_{surv} \\times \\eta_{bind} \\times \\eta_{int} \\times \\eta_{esc} \\times \\eta_{nuc}$$\nSubstituting the given values:\n$$\\eta_{total} = (0.60) \\times (0.60) \\times (0.05) \\times (0.40) \\times (0.25) \\times (0.30)$$\n$$\\eta_{total} = 0.36 \\times 0.05 \\times 0.40 \\times 0.25 \\times 0.30$$\n$$\\eta_{total} = 0.018 \\times 0.40 \\times 0.25 \\times 0.30$$\n$$\\eta_{total} = 0.0072 \\times 0.25 \\times 0.30$$\n$$\\eta_{total} = 0.0018 \\times 0.30$$\n$$\\eta_{total} = 0.00054 = 5.4 \\times 10^{-4}$$\n\nThe mean number of productive genome delivery events per cell, which we denote as $\\lambda$ (the parameter of the Poisson distribution), is the total number of expected productive events in the culture divided by the total number of cells. The total number of productive events is the initial number of vector genomes, $N_{vg}$, multiplied by the overall efficiency, $\\eta_{total}$.\n$$\\lambda = \\frac{N_{vg} \\times \\eta_{total}}{N_{cell}}$$\nSubstituting the calculated and given values:\n$$\\lambda = \\frac{(2.0 \\times 10^{10}) \\times (5.4 \\times 10^{-4})}{3.0 \\times 10^{7}}$$\n$$\\lambda = \\frac{10.8 \\times 10^{6}}{3.0 \\times 10^{7}} = \\frac{1.08 \\times 10^{7}}{3.0 \\times 10^{7}} = 0.36$$\nThus, the mean number of productive genome delivery events per cell is $0.36$. This is the MOI as defined in the problem.\n\nThe problem requires the fraction of transduced cells, defined as the fraction of cells that receive at least one productive genome delivery event. If the number of events per cell, $k$, follows a Poisson distribution with mean $\\lambda$, the probability of a cell receiving exactly $k$ events is given by:\n$$P(k; \\lambda) = \\frac{\\lambda^k \\exp(-\\lambda)}{k!}$$\nThe fraction of cells that are *not* transduced is the probability of a cell receiving zero events, $P(k=0)$.\n$$P(k=0; \\lambda=0.36) = \\frac{(0.36)^0 \\exp(-0.36)}{0!} = \\exp(-0.36)$$\nThe fraction of transduced cells is the complement, $P(k \\ge 1)$.\n$$P(k \\ge 1) = 1 - P(k=0) = 1 - \\exp(-0.36)$$\nNow, we compute the numerical value.\n$$P(k \\ge 1) = 1 - 0.6976763...$$\n$$P(k \\ge 1) = 0.3023236...$$\nThe problem requires the final answer to be rounded to four significant figures.\n$$P(k \\ge 1) \\approx 0.3023$$\nThis is the predicted fraction of transduced cells after the single exposure.",
            "answer": "$$ \\boxed{0.3023} $$"
        },
        {
            "introduction": "Translating an AAV vector from the lab to the clinic requires a deep understanding of its behavior within a whole organism, a field known as pharmacokinetics (PK). AAV vectors, once infused, do not remain in the bloodstream but distribute into various tissues, with the liver being a key target for many therapies. In this problem , you will use a two-compartment PK model to derive and calculate the steady-state concentration ratio of an AAV vector between the liver and plasma. This exercise illustrates how fundamental principles of mass balance and reaction kinetics are used to predict a therapy's biodistribution, which is critical for assessing both efficacy and safety.",
            "id": "5016981",
            "problem": "Adeno-Associated Virus (AAV) gene therapy vectors administered intravenously distribute between plasma and tissues according to first-order kinetics under conditions well below saturation. Consider a well-mixed two-compartment Pharmacokinetic (PK) model with a central plasma compartment and a liver tissue compartment. Let the central compartment have volume $V_{p}$ and the liver compartment have volume $V_{\\ell}$. The vector transfers from plasma to liver with first-order rate constant $k_{12}$ and returns from liver to plasma with first-order rate constant $k_{21}$. Vector is cleared from plasma (e.g., by uptake into non-hepatic tissues or neutralization) with first-order rate constant $k_{el}$. A constant intravenous infusion at rate $R_{in}$ has been running long enough that the system is at steady state. Assume linear kinetics, no saturable binding, and that elimination occurs only from the plasma compartment.\n\nUsing conservation of mass at steady state and the definitions of concentration $C_{p} = A_{p}/V_{p}$ and $C_{\\ell} = A_{\\ell}/V_{\\ell}$, where $A_{p}$ and $A_{\\ell}$ are the amounts of vector in plasma and liver, respectively, derive from first principles an expression for the steady-state liver-to-plasma concentration ratio $C_{\\ell}/C_{p}$ in terms of $k_{12}$, $k_{21}$, $V_{p}$, and $V_{\\ell}$. Then, evaluate this ratio for the following physiologically plausible parameters for an adult subject: $k_{12} = 0.70 \\ \\mathrm{h}^{-1}$, $k_{21} = 0.25 \\ \\mathrm{h}^{-1}$, $k_{el} = 0.15 \\ \\mathrm{h}^{-1}$, $V_{p} = 3.0 \\ \\mathrm{L}$, and $V_{\\ell} = 1.8 \\ \\mathrm{L}$.\n\nExpress your final answer as a pure number with no units, and round your answer to $3$ significant figures.",
            "solution": "The user wants me to solve a two-compartment pharmacokinetic model problem.\n\n### Step 1: Extract Givens\n- **Model**: Two-compartment Pharmacokinetic (PK) model (central plasma compartment and liver tissue compartment).\n- **Volumes**: Central compartment volume $V_{p}$, liver compartment volume $V_{\\ell}$.\n- **Rate Constants**:\n    - Transfer from plasma to liver: $k_{12}$ (first-order).\n    - Transfer from liver to plasma: $k_{21}$ (first-order).\n    - Elimination from plasma: $k_{el}$ (first-order).\n- **Input**: Constant intravenous infusion at rate $R_{in}$.\n- **Condition**: The system is at steady state.\n- **Definitions**:\n    - Plasma concentration: $C_{p} = A_{p}/V_{p}$, where $A_{p}$ is the amount of vector in plasma.\n    - Liver concentration: $C_{\\ell} = A_{\\ell}/V_{\\ell}$, where $A_{\\ell}$ is the amount of vector in liver.\n- **Numerical Values**:\n    - $k_{12} = 0.70 \\ \\mathrm{h}^{-1}$\n    - $k_{21} = 0.25 \\ \\mathrm{h}^{-1}$\n    - $k_{el} = 0.15 \\ \\mathrm{h}^{-1}$\n    - $V_{p} = 3.0 \\ \\mathrm{L}$\n    - $V_{\\ell} = 1.8 \\ \\mathrm{L}$\n\n### Step 2: Validate Using Extracted Givens\nThe problem describes a standard, linear two-compartment pharmacokinetic model, which is a fundamental and well-established concept in pharmacology and biomedical engineering.\n\n- **Scientifically Grounded**: The model is based on first-order kinetics and mass balance, which are core principles in physical chemistry and engineering. This is scientifically sound.\n- **Well-Posed**: The problem asks for a specific ratio ($C_{\\ell}/C_{p}$) at steady state. The assumption of steady state simplifies the governing differential equations to a system of algebraic equations, which allows for a unique, stable, and meaningful solution.\n- **Objective**: The problem is stated using precise, formal language and mathematical definitions, with no subjective or ambiguous terms.\n- **Completeness**: All necessary information to derive the symbolic ratio and calculate its numerical value is provided. The variables $R_{in}$ and $k_{el}$ are part of the full model description, and it is a part of the derivation to determine if they are needed for the final requested ratio.\n- **Realism**: The provided parameters are explicitly stated to be \"physiologically plausible,\" which is consistent with typical values in the literature for plasma volume, liver volume, and distribution/elimination rates in humans.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is a well-posed, scientifically grounded problem in pharmacokinetics. I will proceed with the solution.\n\nThe problem requires the derivation of the steady-state liver-to-plasma concentration ratio, $\\frac{C_{\\ell}}{C_{p}}$, from first principles. This begins with setting up the mass balance equations for the amount of AAV vector in the plasma compartment ($A_{p}$) and the liver compartment ($A_{\\ell}$).\n\nThe rate of change of the amount of vector in the plasma compartment is described by:\n$$\n\\frac{dA_{p}}{dt} = \\text{Rate In} - \\text{Rate Out}\n$$\nThe rates into the plasma compartment are the constant infusion rate, $R_{in}$, and the return from the liver compartment, $k_{21}A_{\\ell}$. The rates out of the plasma compartment are the transfer to the liver compartment, $k_{12}A_{p}$, and the elimination from the system, $k_{el}A_{p}$.\nThus, the differential equation for the plasma compartment is:\n$$\n\\frac{dA_{p}}{dt} = R_{in} + k_{21}A_{\\ell} - k_{12}A_{p} - k_{el}A_{p}\n$$\n\nSimilarly, the rate of change of the amount of vector in the liver compartment is described by:\n$$\n\\frac{dA_{\\ell}}{dt} = \\text{Rate In} - \\text{Rate Out}\n$$\nThe rate into the liver compartment is the transfer from the plasma compartment, $k_{12}A_{p}$. The rate out of the liver compartment is the return to the plasma compartment, $k_{21}A_{\\ell}$.\nThus, the differential equation for the liver compartment is:\n$$\n\\frac{dA_{\\ell}}{dt} = k_{12}A_{p} - k_{21}A_{\\ell}\n$$\n\nThe problem states that the system is at steady state. At steady state, the net rate of change of the amount of substance in each compartment is zero. Therefore, we set the time derivatives to zero:\n$ \\frac{dA_{p}}{dt} = 0 $ and $ \\frac{dA_{\\ell}}{dt} = 0 $.\n\nApplying the steady-state condition to the liver compartment equation gives:\n$$\n0 = k_{12}A_{p} - k_{21}A_{\\ell}\n$$\nThis equation shows that at steady state, the rate of vector transfer from plasma to liver is equal to the rate of vector transfer from liver back to plasma. Rearranging this equation yields a relationship between the amounts of vector in the two compartments:\n$$\nk_{21}A_{\\ell} = k_{12}A_{p}\n$$\n$$\n\\frac{A_{\\ell}}{A_{p}} = \\frac{k_{12}}{k_{21}}\n$$\nNote that this relationship is independent of the infusion rate $R_{in}$ and the elimination rate constant $k_{el}$. These parameters determine the absolute steady-state amounts, but not their ratio as established by the intercompartmental exchange.\n\nThe goal is to find the ratio of concentrations, $\\frac{C_{\\ell}}{C_{p}}$. Using the given definitions, $C_{p} = \\frac{A_{p}}{V_{p}}$ and $C_{\\ell} = \\frac{A_{\\ell}}{V_{\\ell}}$, we can express the amounts $A_{p}$ and $A_{\\ell}$ in terms of concentrations and volumes:\n$$\nA_{p} = C_{p}V_{p}\n$$\n$$\nA_{\\ell} = C_{\\ell}V_{\\ell}\n$$\n\nSubstitute these expressions into the ratio of amounts:\n$$\n\\frac{C_{\\ell}V_{\\ell}}{C_{p}V_{p}} = \\frac{k_{12}}{k_{21}}\n$$\nNow, we can isolate the desired concentration ratio $\\frac{C_{\\ell}}{C_{p}}$ by rearranging the equation:\n$$\n\\frac{C_{\\ell}}{C_{p}} = \\frac{k_{12}}{k_{21}} \\frac{V_{p}}{V_{\\ell}}\n$$\nThis is the symbolic expression for the steady-state liver-to-plasma concentration ratio.\n\nThe final step is to evaluate this expression using the given numerical values:\n- $k_{12} = 0.70 \\ \\mathrm{h}^{-1}$\n- $k_{21} = 0.25 \\ \\mathrm{h}^{-1}$\n- $V_{p} = 3.0 \\ \\mathrm{L}$\n- $V_{\\ell} = 1.8 \\ \\mathrm{L}$\n\nSubstituting these values into the derived formula:\n$$\n\\frac{C_{\\ell}}{C_{p}} = \\frac{0.70}{0.25} \\times \\frac{3.0}{1.8}\n$$\nFirst, calculate the individual ratios:\n$$\n\\frac{0.70}{0.25} = \\frac{70}{25} = \\frac{14}{5} = 2.8\n$$\n$$\n\\frac{3.0}{1.8} = \\frac{30}{18} = \\frac{5}{3}\n$$\nNow, multiply these results:\n$$\n\\frac{C_{\\ell}}{C_{p}} = 2.8 \\times \\frac{5}{3} = \\frac{14}{5} \\times \\frac{5}{3} = \\frac{14}{3}\n$$\nThe decimal representation is:\n$$\n\\frac{14}{3} = 4.666...\n$$\nThe problem asks for the answer to be rounded to $3$ significant figures.\n$$\n\\frac{C_{\\ell}}{C_{p}} \\approx 4.67\n$$\nThe final result is a dimensionless number, as expected for a ratio of concentrations.",
            "answer": "$$\n\\boxed{4.67}\n$$"
        }
    ]
}